Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
44 Cards in this Set
- Front
- Back
|
cyclosporine's MOA?
|
Binds to cyclophilins. Complex blocks the differentiation and activation of T cells by inhibiting calcineurin, thus preventing the production of IL-2 and its receptor.
|
|
|
Tacrolimu (FK506) MOA?
|
Similar to cyclosporine; binds to FK-binding protein, inhibiting secretion of IL-2 and other cytokines
|
|
|
Sirolimus (rapamycin) MOA?
|
Inhibits mTOR. Inhibits T cell proliferation in response to IL-2
|
|
|
Daclizumab MOA?
|
Monoclonal antibody with high affinity for the IL-2 Receptor on activated T cells
|
|
|
Azathioprine MOA?
|
Antimetabolite precursor of 6-mercaptopurine that interferes with the metabolism and synthesis of nucleic acids. Toxic to proliferating lymphocytes.
|
|
|
Muromonab-CD3 (OKT3) MOA?
|
Monoclonal Ab that binds to CD3 (epsilon chain) on the surface of T cells. Blocks cellular interaction with CD3 protein responsible for T cell signal transduction.
|
|
|
Cyclosporine - clinical use?
|
1. suppresses organ rejection after transplantation
2. selected autoimmune disorders |
|
|
Tacrolimus (FK506) - clinical use?
|
Potent immunosuppressive used in organ transplant recipients.
|
|
|
Sirolimus (rapamycin) - clinical use?
|
1. Immunosuppression after kidney transplantation in combo w/cyclosporine and corticosteroids
2. also used w/drug eluting stents |
|
|
Daclizumab - clinical use?
|
Prevents acute rejection of renal transplant
|
|
|
Azathioprine - clinical use?
|
1. Kidney transplantation
2. Autoimmune disorders (including glomerulonephritis and hemolytic anemia) |
|
|
Muromonab-CD3 (OKT3) - clinical use?
|
Immunosuppression after kidney transplant
|
|
|
Cyclosporine toxicity?
|
1. Predisposes patient to viral infections and lymphoma
2. nephrotoxic (preventable with mannitol diuretics) 3. gout |
|
|
Tacrolimus (FK506) toxicity?
|
SIGNIFICANT!! (think Neil Patrick Harris, NPH... NPPHH)
1. nephrotoxicity 2. Peripheral neuropathy 3. Pleural Effusion 4. Hypertension 5. Hyperglycemia |
|
|
Sirolimus (rapamycin) toxicity?
|
1. Hyperlipidemia
2. Thrombocytopenis 3. leukopenia |
|
|
Azathiprine toxicity?
|
1. BM suppression
2. Active metabolite mercaptopurine is metabolized by xanthine oxidase so toxic effects may be increased by allopurinol! * |
|
|
Muromonab-CD3 (OKT3) toxicity?
|
1. Cytokine release syndrome
2. Hypersensitivity Rxn |
|
|
Aldesleukin use?
|
1. Renal Cell Carcinoma
2. Metastatic melanoma |
|
|
Erythropoietin use?
|
Anemias (especially in renal failure)
|
|
|
Filgrastim use?
|
Recovery of bone marrow
|
|
|
Sargramostim use?
|
recovery of BM
|
|
|
alpha interferon use?
|
1. Hepatitis B, C
2. Kaposi's Sarcoma 3. Leukemias 4. Malignant Melanoma |
|
|
beta interferon use?
|
Multiple sclerosis
|
|
|
gamma interferon use?
|
chronic granulomatous disease
|
|
|
oprelvekin (interleukin 11) use?
|
thrombocytopenia
|
|
|
Thrombopoietin use?
|
thrombocytopenia
|
|
|
Muromonab-CD3 (OKT3) target?
|
CD3
|
|
|
Muromonab-CD3 (OKT3) clinical use?
|
prevent acute transplant rejection
|
|
|
Daclizumab target?
|
IL-2 Receptor
|
|
|
Daclizumab clinical use?
|
prevent acute rejection of renal transplant
|
|
|
Digoxin Immune Fab target?
|
Digoxin
|
|
|
Digoxin Immune Fab clinical use?
|
antidote for digoxin toxicity
|
|
|
Infliximab target?
|
TNF-alpha
|
|
|
Infliximab clinical use?
|
1. Crohn's disease
2. rheumatoid arthritis 3. Psoriatic Arthritis 4. Ankylosing Spondylitis |
|
|
Adalimumab target?
|
TNF-alpha
|
|
|
Adalimumab clinical use?
|
1. Crohn's disease
2. rheumatoid arthritis 3. Psoriatic Arthritis |
|
|
Abciximab target?
|
glycoprotein 2b/3a
|
|
|
Abciximab clinical use?
|
Prevent cardiac ischemia in unstable angina and in patients treated with percutaneous coronary intervention (PCI)
|
|
|
Trastuzumab (Herceptin) target?
|
erb-B2
|
|
|
Trastuzumab (Herceptin) clinical use?
|
Her-2 - overexpressing breast cancer
|
|
|
Rituximab target?
|
CD20
|
|
|
Rituximab clinical use?
|
B-cell non-Hodgkin's lymphoma
|
|
|
Omalizumab target?
|
IgE
|
|
|
Omalizumab clinical use?
|
Additional line of Tx for severe asthma
|
